ArticleNeurology(R) neuroimmunology & neuroinflammation2019
Gadolinium in human brain sections and colocalization with other elements.
Open access · goldAbstract read
In one paragraph
Article in Neurology(R) neuroimmunology & neuroinflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 24 citations in OpenAlex.
- High-resolution quantitative mapping of extracellular pH by ratiometric MRI with iron chelates in a tumor mouse model.La Radiologia medica · 2025Article
- Iron and Alzheimer's Disease: From Pathology to Imaging.Frontiers in human neuroscience · 2022Review
- Gadolinium distribution in kidney tissue determined and quantified by micro synchrotron X-ray fluorescence.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2021Article
- Article
- Transient enlargement of brain ventricles during relapsing-remitting multiple sclerosis and experimental autoimmune encephalomyelitis.JCI insight · 2020Article
- Retention of Gadolinium in Brain Parenchyma: Pathways for Speciation, Access, and Distribution. A Critical Review.Journal of magnetic resonance imaging : JMRI · 2020Review
- Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.Frontiers in neurology · 2020Review
- Investigation of potential adverse central nervous system effects after long term oral administration of gadolinium in mice.PloS one · 2020Article
- Gadolinium deposition in the brain of dogs after multiple intravenous administrations of linear gadolinium based contrast agents.PloS one · 2020Article
- Suggestions for improving the design of clinical trials in multiple sclerosis-results of a systematic analysis of completed phase III trials.The EPMA journal · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Ahmed H El-KhatibDepartment of Chemistry (A.H.E.-K., S.T., M.W.L.), Humboldt-Universität zu Berlin, Germany; Pharmaceutical Analytical Chemistry Department (A.H.E.-K.), Faculty of pharmacy, Ain Shams University, Cairo, Egypt; Bundesanstalt für Materialforschung und -prüfung (BAM) (A.H.E.-K., N.J.), Berlin, Germany; Department of Neuropathology (H.R., A.K.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Proteome Factory AG (B.N.), Berlin, Germany; Institute of Pharmacology (B.N.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; NeuroCure Clinical Research Unit Charité-Universitätsmedizin Berlin (F.P.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; and Department of Radiology (E.S.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Helena RadbruchDepartment of Chemistry (A.H.E.-K., S.T., M.W.L.), Humboldt-Universität zu Berlin, Germany; Pharmaceutical Analytical Chemistry Department (A.H.E.-K.), Faculty of pharmacy, Ain Shams University, Cairo, Egypt; Bundesanstalt für Materialforschung und -prüfung (BAM) (A.H.E.-K., N.J.), Berlin, Germany; Department of Neuropathology (H.R., A.K.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Proteome Factory AG (B.N.), Berlin, Germany; Institute of Pharmacology (B.N.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; NeuroCure Clinical Research Unit Charité-Universitätsmedizin Berlin (F.P.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; and Department of Radiology (E.S.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Sabrina TrogDepartment of Chemistry (A.H.E.-K., S.T., M.W.L.), Humboldt-Universität zu Berlin, Germany; Pharmaceutical Analytical Chemistry Department (A.H.E.-K.), Faculty of pharmacy, Ain Shams University, Cairo, Egypt; Bundesanstalt für Materialforschung und -prüfung (BAM) (A.H.E.-K., N.J.), Berlin, Germany; Department of Neuropathology (H.R., A.K.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Proteome Factory AG (B.N.), Berlin, Germany; Institute of Pharmacology (B.N.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; NeuroCure Clinical Research Unit Charité-Universitätsmedizin Berlin (F.P.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; and Department of Radiology (E.S.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Boris NeumannDepartment of Chemistry (A.H.E.-K., S.T., M.W.L.), Humboldt-Universität zu Berlin, Germany; Pharmaceutical Analytical Chemistry Department (A.H.E.-K.), Faculty of pharmacy, Ain Shams University, Cairo, Egypt; Bundesanstalt für Materialforschung und -prüfung (BAM) (A.H.E.-K., N.J.), Berlin, Germany; Department of Neuropathology (H.R., A.K.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Proteome Factory AG (B.N.), Berlin, Germany; Institute of Pharmacology (B.N.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; NeuroCure Clinical Research Unit Charité-Universitätsmedizin Berlin (F.P.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; and Department of Radiology (E.S.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Friedemann PaulDepartment of Chemistry (A.H.E.-K., S.T., M.W.L.), Humboldt-Universität zu Berlin, Germany; Pharmaceutical Analytical Chemistry Department (A.H.E.-K.), Faculty of pharmacy, Ain Shams University, Cairo, Egypt; Bundesanstalt für Materialforschung und -prüfung (BAM) (A.H.E.-K., N.J.), Berlin, Germany; Department of Neuropathology (H.R., A.K.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Proteome Factory AG (B.N.), Berlin, Germany; Institute of Pharmacology (B.N.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; NeuroCure Clinical Research Unit Charité-Universitätsmedizin Berlin (F.P.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; and Department of Radiology (E.S.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Arend KochDepartment of Chemistry (A.H.E.-K., S.T., M.W.L.), Humboldt-Universität zu Berlin, Germany; Pharmaceutical Analytical Chemistry Department (A.H.E.-K.), Faculty of pharmacy, Ain Shams University, Cairo, Egypt; Bundesanstalt für Materialforschung und -prüfung (BAM) (A.H.E.-K., N.J.), Berlin, Germany; Department of Neuropathology (H.R., A.K.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Proteome Factory AG (B.N.), Berlin, Germany; Institute of Pharmacology (B.N.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; NeuroCure Clinical Research Unit Charité-Universitätsmedizin Berlin (F.P.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; and Department of Radiology (E.S.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Michael W LinscheidDepartment of Chemistry (A.H.E.-K., S.T., M.W.L.), Humboldt-Universität zu Berlin, Germany; Pharmaceutical Analytical Chemistry Department (A.H.E.-K.), Faculty of pharmacy, Ain Shams University, Cairo, Egypt; Bundesanstalt für Materialforschung und -prüfung (BAM) (A.H.E.-K., N.J.), Berlin, Germany; Department of Neuropathology (H.R., A.K.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Proteome Factory AG (B.N.), Berlin, Germany; Institute of Pharmacology (B.N.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; NeuroCure Clinical Research Unit Charité-Universitätsmedizin Berlin (F.P.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; and Department of Radiology (E.S.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Norbert JakubowskiDepartment of Chemistry (A.H.E.-K., S.T., M.W.L.), Humboldt-Universität zu Berlin, Germany; Pharmaceutical Analytical Chemistry Department (A.H.E.-K.), Faculty of pharmacy, Ain Shams University, Cairo, Egypt; Bundesanstalt für Materialforschung und -prüfung (BAM) (A.H.E.-K., N.J.), Berlin, Germany; Department of Neuropathology (H.R., A.K.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Proteome Factory AG (B.N.), Berlin, Germany; Institute of Pharmacology (B.N.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; NeuroCure Clinical Research Unit Charité-Universitätsmedizin Berlin (F.P.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; and Department of Radiology (E.S.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Eyk SchellenbergerDepartment of Chemistry (A.H.E.-K., S.T., M.W.L.), Humboldt-Universität zu Berlin, Germany; Pharmaceutical Analytical Chemistry Department (A.H.E.-K.), Faculty of pharmacy, Ain Shams University, Cairo, Egypt; Bundesanstalt für Materialforschung und -prüfung (BAM) (A.H.E.-K., N.J.), Berlin, Germany; Department of Neuropathology (H.R., A.K.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Proteome Factory AG (B.N.), Berlin, Germany; Institute of Pharmacology (B.N.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; NeuroCure Clinical Research Unit Charité-Universitätsmedizin Berlin (F.P.), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; and Department of Radiology (E.S.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Humboldt-Universität zu Berlin · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Brain ChemistryAgedBrainBrain MappingContrast MediaFemaleGadoliniumHumansMagnetic Resonance ImagingMaleMiddle AgedContrast MediaGadolinium
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.